The circadian clock is an endogenous timekeeper that synchronises biological processes with daily external rhythms such as light and temperature cycles. It provides organisms with a competitive advantage by allowing anticipation of daily events. The circadian clock encompasses a network of transcription-translational feedback loops (TTFLs) that orchestrates rhythmic expression of a large part of the genome. This network is regulated at post-transcriptional and post-translational level. Post-translational regulation of clock proteins is essential to ensure stable rhythms and robust timekeeping. Unlike the genes in the TTFL network, modifiers of clock proteins at post-translational level are conserved across taxa. SUMO, a small ubiquitin-related post-translational modifier, regulates timekeeping in mammals through modification of the clock transcription factor BMAL. In this study, SUMO is shown to contribute to oscillator function in Arabidopsis plants. Methods have been developed to prove that mutant lines defective in SUMO machinery, including SUMO-ligase and -protease mutants, display long circadian rhythms. Additionally, sumoylation on the crucial plant clock transcription factor CCA1 is observed in vivo. A fraction of the protein is sumoylated across the expression window of CCA1, with the phase of peak sumoylation in advance of peak total CCA1. The effect of sumoylation of CCA1 was investigated with respect to localisation, stability and DNA binding affinity of the protein, as these are previously described possible effects of sumoylation. The subcellular location of CCA1-YFP fusions in protoplasts was not altered in mutant lines of the SUMO machinery. In vitro experiments show that sumoylation negatively affects the affinity of CCA1 to its cognate promotor element, suggesting that SUMO could act as a reversible attenuator of CCA1 activity. Furthermore, effects of SUMO machinery mutations appear to be differential across a range of physiologically relevant temperatures, implying that sumoylation could be involved in the response to or buffering against fluctuating ambient temperatures. There is an increasing amount of evidence to suggest that metabolic oscillations are not only driven by transcriptional outputs of the clock, but are to some extent self-sustained and can feed timing information back into the clock. Glutathione was investigated as a possible metabolic feedback signal. Expression of clock gene CCA1 was found to be abolished in a mutant of the rate-limiting enzyme for glutathione synthesis (pad2-1). Surprisingly however, the amount of glutathione was not found to oscillate. Combined, the results discussed in this thesis provide a substantial advance on our understanding of post-translational regulation and the integration of metabolic and environmental information into the plant circadian clock.

Abstract: TSG101 is a tumor susceptibility gene exhibits multiple biological function, including the regulation of cell progression, intracellular protein sorting and membrane trafficking, and transcription activity of nuclear recptor such as estrogen recptor. TSG101 contains an UBC domain which is homologous to that in ubiquitin conjugating E2 enzyme. However, it lacks an essential cysteine residue, which is essential for catalytic activity. Cellular protein ubiquitination serves as a signal for protein degradation or sorting into multivesicular body. UBC domain of TSG101 was proved to contain amino acid residues that are important for its interaction with ubquitin (residues V43, N46, D46 and F88) and PTAP sequence found in the late domain of HIV gag protein (residues Y63, M95, V141). SUMO is an ubquitin-like modifier which can modify cellular protein harbors £ZKXE amino acid sequence, thereby change its subcellular localization and biological activities. TSG101 protein contains K98, K243, K264 and K269 residues that localize in potential SUMO modification site. Our preliminary data indicated that TSG101 colocalize with SUMO in nucleus. It is interesting to know whether TSG101 is sumoylated, and its functional significance. In this thesis, a series of site-directed mutageneic mutant HA and GFP-tagged expression plasmids which contain mutation of the above mentioned functional related amino acid residues were constructed for future TSG101 functional studies.

Stress conditions such as heat shock, UV, alkylating agents, and H2O2 have been shown to result in the modification of a variety of protein targets via the production of reactive electrophiles. These modifications can directly impact protein function or can alter posttranslational modifications, thus leading to a disruption of cellular regulatory processes. Recent studies have shown that stress-induced protein modifications can modulate posttranslational modification by the small ubiquitin related modifier (SUMO) family of proteins. Unlike ubiquitination, which primarily targets proteins for proteasomal degradation, sumoylation exerts a variety of effects including protein stabilization, subcellular localization, and the alteration of protein-protein interactions and transcriptional activity. To investigate the effects of alkylation and oxidative stress on sumoylation, HEK293 cells were treated with iodoacetamide, hydroquinone, benzoquinone, Texas Red C5 bromoacetamide, hydrogen peroxide, and 4-hydroxynonenal (HNE), a highly reactive product of lipid peroxidation associated with oxidative stress. Western blot analysis revealed that the agents tested resulted in concentration-dependent changes in the patterns of SUMO-1 and SUMO-2/3 protein conjugation. Localization studies using western blot analysis and confocal immunofluorescence microscopy demonstrated that SUMO-1 protein conjugates were located primarily in the nucleus, whereas SUMO-2/3 protein conjugates were more equally distributed between the nucleus and the cytoplasm. SUMO-associated proteins were harvested from vehicle- and HNE-treated non-transfected HEK293 cells using agarose conjugated anti-SUMO-1 antibodies or from HA-SUMO-1- and HA-SUMO-3-expressing HEK293 cells using immunoaffinity chromatography. Multidimensional liquid chromatography-tandem mass spectrometry analyses resulted in the identification of 54 HA-SUMO-1-associated proteins and 37 HA-SUMO-3-associated proteins in vehicle-treated cells and 21 HA-SUMO-1- and HA-SUMO-3-associated proteins in HNE treated cells. Additionally, 27 SUMO-1-associated proteins were identified in the HNE-treated non-transfected cells. The functional classes of proteins targeted included RNA binding and processing proteins, metabolic enzymes, cytoskeletal regulators, and chaperone proteins. HNE treatment resulted in a near complete redistribution of both SUMO-1 and SUMO-3 to different targets. There was a 15% overlap in SUMO-1 and SUMO-3 associated proteins in vehicle-treated cells and a 10% overlap in HNE-treated cells indicating that SUMO proteins target distinct protein groups. These results indicate that protein modifying reactive electrophiles can regulate protein functions through the indirect alteration of endogenous posttranslational modifications.

Une large gamme d’événements cellulaires est régulée par la SUMOylation des protéines. Cette modification post-traductionnelle est impliquée dans le cancer notamment dans la leucémie promyélocytaire aigue. À ce jour, peu d’études à grande échelle ont porté sur l’identification des sites de modification. Ce mémoire présente une approche protéomique quantitative unique qui combine une double purification par affinité au niveau des protéines cibles ainsi que des peptides modifiés. L’approche la plus répandue de purification des protéines SUMOylés implique l’utilisation d’une forme de SUMO modifié avec une étiquette (His6-SUMO). A ce jour, les approches permettant l’enrichissement au niveau peptidique nécessite une forme mutante de SUMO. Notre analyse consiste à premièrement enrichir en protéines SUMOylés dans les cellules humaines vierges ou sur exprimant His6-SUMO-1/3 en présence ou pas de trioxyde de diarsenic, un traitement de leucémie promyélocytaire aigue. Par la suite, les échantillons sont digérés et les peptides obtenus des protéines SUMOylés conservent un branchement caractéristique. Les peptides sont soit immunoprécipités avec un anticorps spécifique au branchement SUMO ou directement analysés par nano LC/LC-MS/MS par un spectromètre de masse LTQ-Orbitrap. Une analyse manuelle des données révèle des fragments caractéristiques correspondant à la chaîne latérale de SUMO. L’originalité de l’approche réside dans l’identification quantitative et sans ambigüité des sites de SUMOylation. Cette approche a permis l’identification de 17 et 3 sites de SUMO-3 et SUMO-1 respectivement dans les cellules HEK293. Finalement, la SUMOylation de PML est induite suite au traitement d’arsenic. / A wide range of cellular events are regulated by protein SUMOylation. This posttranslational modification was involved in APL (acute promyelocytic leukemia). Only a few large scale studies in mammalian cells have focused on identifying the conjugation sites. This thesis presents a unique quantitative proteomics approach that combines double affinity purification at the protein and peptide level. A common approach to purification of SUMOylated proteins involves the use of a tagged SUMO (His6-SUMO). To date, the SUMO peptide isolation is addressed using an engineered SUMO. In presence or absence of arsenic trioxide, a treatment of APL, mock and His6-SUMO1/3 expressing cells are lysed and the SUMOylated proteins are isolated under denaturing conditions. Subsequently, these samples are digested and the peptides bearing the modification site bear a specific SUMO stub. They are either immunoprecipitated with an anti SUMO stub antibody or directly analyzed by nano LC coupled to an LTQ-Orbitrap mass spectrometer. Manual analysis of the data reveals characteristic fragmentation corresponding to the side chain of SUMO. The originality of the approach lies in the quantitative and unambiguous identification of SUMOylation sites in vivo. This approach allowed the identification of 17 and 3 sites of SUMO-3 and SUMO-1, respectively, in HEK293 cells. Finally, PML was identified as the major SUMOylation target following arsenic treatment. / Les fichiers qui accompagnent mon document sont des tableaux supplémentaires réalisés avec Excel (Microsoft Office), dans la version papier du mémoire ces fichiers sont sur un CD-ROM.

CRTR-1 is a member of the CP2 family of transcription factors. Unlike other CP2 family members, CRTR-1 expression is regulated developmentally. Major sites of expression in the embryo include the pluripotent inner cell mass (ICM) of the pre-implantation blastocyst and the developing kidney. It is also expressed in embryonic stem (ES) cells, which are derived from the ICM of blastocysts, and is downregulated as these cells differentiate into early primitive ectoderm-like (EPL) cells. This expression pattern suggests that CRTR-1 plays a role in early pluripotent populations. This thesis aims to characterize the transcription factor CRTR-1 at the molecular level and analyses the role of sumoylation on CRTR-1 function to develop a better understanding of the molecular role of CRTR-1 in ES cells. Luciferase reporter assays show that CRTR-1 is able to regulate the activities of other CP2 family members: CP2, NF2d9 and altNF2d9. It enhances CP2- and NF2d9-mediated activation but suppresses altNF2d9-mediated activation. To map the functional domains in the CRTR-1 protein, transactivation studies using CRTR-1 deletion mutants fused to the GAL4 DNA binding domain and a GAL4-responsive reporter system were performed. These studies map repressor activity to amino acids 48-200, but fail to identify a transactivation domain within the CRTR-1 protein. In order to understand the mechanisms by which CRTR-1 regulates the transcriptional activities of CP2 family members, a number of approaches are taken, including co-immunoprecipitation to show that CRTR-1 interacts with other CP2-like proteins, EMSA which demonstrate that CRTR-1 forms DNA binding complexes with CP2 family members, and subcellular protein localisation studies which reveal the ability of CRTR-1 and other family members to shuttle between the nucleus and cytoplasm via a CRM1-dependent pathway. In addition, the subcellular localisation of CRTR-1 appears to be cell type specific, with an exclusively nuclear localisation pattern in ES cells, a predominantly cytoplasmic localisation pattern in HEK293T cells, and a cytoplasmic and nuclear speckle localisation pattern in COS-1 cells. Co-expression of CRTR-1 with CP2 or NF2d9 results in the re-localisation of CRTR-1 to the cytoplasm in ES cells. The sumoylation enzymes Ubc9 and PIAS1 have previously been identified as CP2-interacting proteins (Kang et al., 2005a). Given the identification of two potential sumoylation sites within CRTR-1, FK³⁰ QE and LK⁴⁶ ⁴AE, and the ability for sumoylation to regulate transcription factor function, the possibility that CRTR-1 is regulated by sumoylation is investigated in this thesis. Immunoprecipitation experiments show that CRTR-1 is modified by SUMO-1 and that lysine 30 is the critical residue for this modification. Mutation of lysine 30 to alanine, which abolishes CRTR-1 sumoylation, results in enhancement of transactivation by CRTR-1, suggesting that sumoylation of CRTR-1 blocks maximal activation. Unexpectedly, however, overexpression of Ubc9, PIAS1, or SUMO-1 results in enhancement of CRTR-1 transcriptional activity, indicating that a more complex mechanism of regulation of CRTR-1 activity is likely. This thesis presents several novel properties of CRTR-1 and other CP2 family members, including the ability of CRTR-1, previously characterized as a repressor, to activate transcription. It is also the first demonstration that CP2 proteins are regulated by sumoylation and that they shuttle between the nucleus and cytoplasm via a CRM1-dependent mechanism. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1374290 / Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, 2009

CRTR-1 is a member of the CP2 family of transcription factors. Unlike other CP2 family members, CRTR-1 expression is regulated developmentally. Major sites of expression in the embryo include the pluripotent inner cell mass (ICM) of the pre-implantation blastocyst and the developing kidney. It is also expressed in embryonic stem (ES) cells, which are derived from the ICM of blastocysts, and is downregulated as these cells differentiate into early primitive ectoderm-like (EPL) cells. This expression pattern suggests that CRTR-1 plays a role in early pluripotent populations. This thesis aims to characterize the transcription factor CRTR-1 at the molecular level and analyses the role of sumoylation on CRTR-1 function to develop a better understanding of the molecular role of CRTR-1 in ES cells. Luciferase reporter assays show that CRTR-1 is able to regulate the activities of other CP2 family members: CP2, NF2d9 and altNF2d9. It enhances CP2- and NF2d9-mediated activation but suppresses altNF2d9-mediated activation. To map the functional domains in the CRTR-1 protein, transactivation studies using CRTR-1 deletion mutants fused to the GAL4 DNA binding domain and a GAL4-responsive reporter system were performed. These studies map repressor activity to amino acids 48-200, but fail to identify a transactivation domain within the CRTR-1 protein. In order to understand the mechanisms by which CRTR-1 regulates the transcriptional activities of CP2 family members, a number of approaches are taken, including co-immunoprecipitation to show that CRTR-1 interacts with other CP2-like proteins, EMSA which demonstrate that CRTR-1 forms DNA binding complexes with CP2 family members, and subcellular protein localisation studies which reveal the ability of CRTR-1 and other family members to shuttle between the nucleus and cytoplasm via a CRM1-dependent pathway. In addition, the subcellular localisation of CRTR-1 appears to be cell type specific, with an exclusively nuclear localisation pattern in ES cells, a predominantly cytoplasmic localisation pattern in HEK293T cells, and a cytoplasmic and nuclear speckle localisation pattern in COS-1 cells. Co-expression of CRTR-1 with CP2 or NF2d9 results in the re-localisation of CRTR-1 to the cytoplasm in ES cells. The sumoylation enzymes Ubc9 and PIAS1 have previously been identified as CP2-interacting proteins (Kang et al., 2005a). Given the identification of two potential sumoylation sites within CRTR-1, FK³⁰ QE and LK⁴⁶ ⁴AE, and the ability for sumoylation to regulate transcription factor function, the possibility that CRTR-1 is regulated by sumoylation is investigated in this thesis. Immunoprecipitation experiments show that CRTR-1 is modified by SUMO-1 and that lysine 30 is the critical residue for this modification. Mutation of lysine 30 to alanine, which abolishes CRTR-1 sumoylation, results in enhancement of transactivation by CRTR-1, suggesting that sumoylation of CRTR-1 blocks maximal activation. Unexpectedly, however, overexpression of Ubc9, PIAS1, or SUMO-1 results in enhancement of CRTR-1 transcriptional activity, indicating that a more complex mechanism of regulation of CRTR-1 activity is likely. This thesis presents several novel properties of CRTR-1 and other CP2 family members, including the ability of CRTR-1, previously characterized as a repressor, to activate transcription. It is also the first demonstration that CP2 proteins are regulated by sumoylation and that they shuttle between the nucleus and cytoplasm via a CRM1-dependent mechanism. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1374290 / Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, 2009

Les Leucémies Aigues Myéloïdes (LAM) sont des hémopathies au pronostic sombre. A l’exception des Leucémies Aigues Promyélocytaires (LAP), un sous type minoritaire de LAM, la plupart des patients sont traités par une chimiothérapie d’induction composée de la cytarabine et d’une anthracycline. Cependant, une fraction importante (20-30%) des patients ne répond pas à la chimiothérapie d’induction et les taux de rechutes sont très élevés.Il n’existe actuellement pas d’outils disponibles au diagnostic permettant de prédire la réponse des patients aux chimiothérapies. De tels tests permettraient d’adapter les doses utilisées pour augmenter le taux de réponse et limiter la toxicité des chimiothérapies, très importante chez les personnes âgées.Les protéines de la famille de l’Ubiquitine (UbL), dont l’ubiquitine, SUMO (-1,-2,-3) et Nedd8 sont les membres les plus étudiés, sont des modificateurs post-traductionnels peptidiques conjugués de façon covalente sur des milliers de protéines. Elles sont impliquées dans la plupart des fonctions cellulaires et dérégulées dans de nombreuses pathologies. De nombreux travaux suggèrent que leur dérégulation est associée à la chimiorésistance des LAM.La première partie de nos travaux a consisté à identifier un ensemble de protéines dont le niveau de modification par l’ubiquitine, SUMO et NEDD8 pourrait constituer des biomarqueurs de la réponse des LAM aux drogues chimiothérapeutiques. Nous avons de plus développé un test permettant d’évaluer leur niveau de modification par des extraits de cellules de patients de manière simple et rapide, utilisable en clinique au diagnostic.Le ciblage des voies Ubiquitine, SUMO et Nedd8 est en train d’apparaître comme une stratégie thérapeutique prometteuse dans les cancers et plusieurs molécules ciblant ces voies ont été récemment décrites. Le développement clinique de ces molécules nécessite la mise au point de tests compagnons pour suivre leur efficacité sur leurs cibles moléculaires. Nous avons ainsi développé un test d’activité permettant de mesurer de façon simple et quantitative l’efficacité des molécules ciblant les modificateurs de la famille de l’ubiquitine,Enfin, compte tenu du potentiel thérapeutique du ciblage de la SUMOylation, nous avons débuté le développement d’un inhibiteur de la SUMOylation basé sur l’inhibition de l’interaction entre les enzymes E1 et E2 par des peptides agrafés. / Acute Myeloid Leukemias (AML) are severe haematological malignancies with a poor prognosis. Except Acute Promyelocytic Leukemia (APL), a minor subtype of AML, most patients receive an induction chemotherapy consisting of cytarabine and an anthracycline. However, a large number (20-30%) of patients do not respond to this induction chemotherapy, and relapses are frequent.There are currently no tools available at diagnosis to predict patient response to chemotherapy. Such tests would make it possible to adapt the doses used to increase the response rate and limit the toxicity of chemotherapies, which is significant in older patients.Ubiquitin-like modifiers (UbL), among which ubiquitin, SUMO (-1, -2, -3) and Nedd8 are the most studied members, are post-translational modifiers covalently conjugated to thousands of proteins. They are involved in most cellular pathways, and deregulated in several pathologies. Many studies suggest that their deregulation is associated with LAM chemoresistance.The first part of our work consisted in identifying a set of proteins whose level of modification by ubiquitin, SUMO and NEDD8 could constitute biomarkers of AMLs response to chemotherapeutic drugs. We have also developed a test to evaluate their level of modification by extracts of patient cells in a simple and rapid manner, usable in clinical diagnosis.Targeting of the Ubiquitin, SUMO and Nedd8 pathways is emerging as a promising therapeutic strategy in cancers and several molecules targeting these pathways have recently been described. The clinical development of these molecules requires the development of companion tests to monitor their efficacy on their molecular targets. We have developed an activity test to measure in a simple and quantitative way the efficacy of molecules targeting ubiquitin-like modifiers.Finally, given the therapeutic potential of targeting SUMOylation, we have started the development of a SUMOylation inhibitor based on the inhibition of the interaction between E1 and E2 enzymes by stapled peptides.

Le but de mon travail était d’étudier les modifications post-traductionnelles et plus précisément la sumoylation d’Ikaros. Mes études ont montré que le facteur de transcription Ikaros est modifié non seulement par SUMO-1 mais aussi par SUMO-2/3 sur plusieurs sites consensus. Cette modification est conditionnelle et dépendante du stade de développement des cellules T. J’ai trouvé un site consensus en plus des sites déjà décrits dans l’étude de Gómez-del Arco et al., 2005. En accord avec les résultats publiés, dans mon système expérimental, l’absence de sumoylation augmente les propriétés anti-prolifératives d’Ikaros, car ses mutants qui ne peuvent pas être sumoylés inhibent mieux la prolifération des cellules leucémiques. Un effet surprenant est l’absence d’un effet cumulatif de l’absence de sumoylation sur la prolifération des cellules. Par exemple, des mutants ponctuels qui ne perdent pas complètement leur sumoylation sont les meilleurs répresseurs de la prolifération, comparés avec le mutant où tous les sites modifiés sont mutés. Ce résultat est en contradiction avec les données publiées, parce qu’il suggère un rôle différent de la sumoylation, et non seulement comme un interrupteur physique des complexes Ikaros – NURD. J’ai fait des expériences utilisant l’expression d’un gène rapporteur comme un moyen de révéler des différences subtiles entre les propriétés répressives d’Ikaros et ses mutants sumo-déficients. Pour ces essais j’ai utilisé des cellules HeLa, un type cellulaire qui n’exprime pas Ikaros endogène et qu’il est donc théoriquement convenable pour étudier son effet sur l’expression d’un gène rapporteur. Mes résultats ont démontré que dans des cellules HeLa, il n’y pas de différence significative entre les propriétés répressives d’Ikaros et ses mutants sumo-déficients. Ces différences par rapport aux résultats obtenues avec la lignée de cellule T suggèrent une grande importance de contexte du système utilisé et que certains effets peuvent être observés uniquement dans des cellules T. Pour mieux comprendre le rôle de la sumoylation dans le fonctionnement d’Ikaros, j’ai analysé les transcriptomes des lignées cellulaires T qui surexpriment IK1-ER ou ses mutants. L’analyse des puces d’ADN a démontré un phénotype de dérégulation d’expression des gènes cibles d’Ikaros, différent entre la protéine WT et les mutants, ainsi qu’entre les mutants mêmes. Ce résultat suggère un rôle de la sumoylation d’Ikaros beaucoup plus complexe que l’interruption mécanique de son interaction avec le complexe NURD. Mes résultats ont aussi démontré que les autres membres de la famille d’Ikaros (Helios, Aiolos et Eos) sont également sumoylés, un événement qui pourrait être important pour la régulation de leurs fonctions. / The main topic of my PhD studies was to investigate the role of sumoylation in the function of Ikaros transcription factor, that regulates the lymphocyte differentiation and function. Sumoylation is a posttranslational modification that can change the properties and regulate the function of a given protein. Up to now, one study addressed the question of how sumoylationmodulates Ikaros function. It shows that Ikaros is sumoylated in total primary thymocytes, and that this dynamic event modulates Ikaros' repressive function. It also describes two consensus sumoylation sites on Ikaros (K58 and K240), the sumoylation of which leads to loss of Ikaros repressive function in ectopic reporter gene assays. The final conclusion of the study is that sumoylation does not alter the nuclear localization of Ikaros but acts as a mechanism disrupting its participation in both histone deacetylase (HDAC) dependent and independent repression. My work shows the presence of additional sumoylation site on Ikaros and demonstrates that sumoylation does not significantly alter its interaction with the nucleosome remodelling and histone deacetylase (NURD) complex in T-cell lines. The functional analysis of sumo-deficientmutants indicates a complex role of this modification in regulating Ikaros' transcriptional properties. The identification of this new sumoylation site contributes to a better understanding of Ikaros' dual repressive - activating function and suggests the existence of conditional Ikaros' interacting partners. Moreover, the different Ikaros splicing isoforms would have differentsumoylation profiles, which would complete the knowledge of their functional diversity.

La SUMOylation est une modification post-traductionnelle essentielle pour toutes les cellules eucaryotes. C’est un processus enzymatique qui permet la liaison covalente du polypeptide SUMO sur des résidus lysine de protéines cibles. La SUMOylation est un processus réversible sous l’action de désumoylases appelées SENP. Il est critique de maintenir un équilibre entre forme modifiée et non modifiée d’un substrat donné. En effet, la dérégulation de la balance SUMOylation/déSUMOylation a été mise en évidence dans plusieurs pathologies cérébrales. La synapse est le point de contact entre les neurones où s’effectue la communication synaptique. Ce sont des structures très denses où le processus de SUMOylation régule l’interaction et la fonction de multiples protéines. Durant ma thèse, j'ai combiné l’utilisation de l'imagerie en temps réel sur cellules vivantes avec des approches biochimiques et pharmacologiques pour identifier les mécanismes de régulation du transport de SENP1. J'ai ainsi démontré que l'activation neuronale augmente les niveaux synaptiques de SENP1. Cette augmentation synaptique résulte de la modification de la vitesse de diffusion de l’enzyme SENP1 entre les dendrites et les synapses d’une part, et d’autre part, de l’augmentation importante du temps de rétention synaptique de l’enzyme. Je rapporte également que ce mécanisme de régulation dynamique de SENP1 implique l'activation des récepteurs métabotropiques du glutamate. De plus, je suggère la participation du processus de phosphorylation dans cette régulation synapto-dendritique de SENP1 mettant ainsi en lumière un nouveau mécanisme de régulation de la balance neuronale entre SUMOylation et déSUMOylation. / Sumoylation is a vital eukaryotic posttranslational modification. Sumoylation occurs as an enzymatic cycle that conjugates SUMO proteins to target proteins. SUMO proteases (SENP) deconjugate SUMO from modified proteins and thus maintain balanced levels of SUMOylated and un-SUMOylated proteins required for physiological homeostasis. Neuronal synapses are protein-rich structures that underlie synaptic transmission and plasticity. Strong evidence exists that sumoylation occurs in synapses and regulates the function of synaptic proteins. Indeed, distortion of the SUMO balance has been linked to several pathologies of the synapse. Gaining a deeper understanding into the molecular mechanisms regulating the SUMO balance is a prerequisite to envisaging the development of novel therapies. In my PhD work, I used a combination of live-cell confocal imaging, protein biochemistry and pharmacological approaches to identify SENP1 regulatory mechanisms at synapses. I provided evidence that synaptic activation increases SENP1 protein levels at synapses. I showed that the increase in synaptic SENP1 upon synaptic activation is a result of two processes: Although (a) fewer SENP1 proteins enter into spines at low diffusion speed (b) a significant proportion of SENP1 becomes immobile and is retained in spines. I demonstrate that the regulatory mechanisms of SENP1 dynamics involve a direct activation of mGlu1/5 receptors. Moreover, I suggest that phosphorylation may play an important regulatory role in SENP1 synapto-dendritic diffusion. Altogether, I propose a novel mechanism driving for the SUMO balance at synapses.

Primary human hepatocytes are a scarce resource with variable function, which diminishes with time in culture. As a consequence their use in tissue modelling and therapy is restricted. Human embryonic stem cells (hESCs) could provide a stable source of human tissue due to their properties of self-renewal and their ability to give rise to all three germ layers. hESCs have the potential to provide an unlimited supply of hepatic endoderm (HE) which could offer efficient tools for drug discovery, disease modelling and therapeutic applications. In order to create a suitable environment to enhance HE formation, hESC culture needed to be standardised. As such, a media trail was carried out to define serum free media capable of maintaining hESC in a pluripotent undifferentiated state. We also ensured hESC cultured in the various media could be directly differentiated to HE in a reproducible and efficient manner. The project then focused on the effect of post-translational modifications (PTMs), specifically SUMOylation, in hepatocyte differentiation and its subsequent manipulation to enhance HE viability. SUMOylation is a PTM known to modify a large number of proteins that play a role in various cellular processes including: cell cycle regulation, gene transcription, differentiation and cellular localisation. We hypothesised that SUMO modification may not only regulate hESC self renewal, but also maybe required for efficient hESC differentiation. We therefore interrogated the role of SUMOylation in hESC differentiation to hepatic endoderm (HE). hESC were differentiated and the cellular lysates were analysed by Western blotting for key proteins which modulate the conjugation and de conjugation of SUMO. We demonstrate that peak levels of SUMOylation were detectable in hESC populations and during cellular differentiation to definitive endoderm (DE), day 5. Following commitment to DE we observed a decrease in the level of SUMO modified proteins during cellular specialisation to a hepatic fate, corresponding with an increase in SENP 1, a SUMO deconjugation enzyme. We also detected reduced levels of hepatocyte nuclear factor 4 α (HNF4α), a critical regulator of hepatic status and metabolic function, as SUMOylation decreased. As a result, we investigated if HNF4α was SUMOylated and if this process was involved in modulating HNF4α’s critical role in HE. HNF4α is an important transcription factor involved in liver organogenesis during development and is a key regulator for efficient adult liver metabolic functions. We observed a decreasing pattern of HNF4α expression at day 17 of our differentiation protocol in conjunction with a decrease in SUMO modified proteins. In order to further investigate and validate a role of SUMOylation on HNF4α stability Immunoprecipitation (IP) was employed. HNF4α protein was pulled down and probed for SUMO 2. Results show an increase in the levels of SUMO2 modification as the levels of HNF4α decrease. Through deletion and mutation analysis we demonstrated that SUMO modification of HNF4α was restricted to the C-terminus on lysine 365. Protein degradation via the proteasome was responsible for the decrease in HNF4α, demonstrated by the use of a proteasome 26S inhibitor MG132. Additionally, a group at the University of Dundee has shown that polySUMOylation of promyelocytic leukaemia protein (PML) leads to its subsequent ubiquitination via RNF4, an ubiquitin E3 ligase, driving its degradation. Using an in vitro ubiquitination assay, we show that polySUMOylated HNF4α is preferentially ubiquitinated in the presence of RNF4. Overall polySUMOylation of HNF4α may reduce its stability by driving its degradation, hence regulating protein activity. In conclusion, polySUMOylation of HNF4α is associated with its stability. HNF4α is subsequently important for HE differentiation both driving the formation of the hepatocytes and in maintaining a mature phenotype, in agreement with a number of different laboratories. Creating the ideal environment for sustaining mature functional hepatocytes, primary and those derived from hESCs and iPSCs, is essential for further use in applications such as drug screening, disease modelling and extracorporeal devices.